Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study.

Autor: Su B; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Yao C; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China., Zhao QX; Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China., Cai WP; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China., Wang M; Institute of HIV/AIDS, the First Hospital of Changsha, Changsha, Hunan 410005, China., Lu HZ; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China., Mu TT; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Chen YY; Department of Infectious Diseases, Infectious Disease Hospital of Henan Province, Zhengzhou, Henan 450061, China., Liu L; Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China., Wang H; Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China., He Y; Department of Infectious Diseases, National Clinical Center for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong 518112, China., Zheng YH; Department of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China., Li LH; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China., Chen JF; Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510060, China., Yu JH; Department of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, Zhejiang 310023, China., Zhu B; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, China., Zhao M; National Clinical Research Center for Infectious Diseases, the Fifth Medical Center of PLA General Hospital, Beijing 100039, China., Sun YT; Department of Infectious Diseases, Tangdu Hospital, the Fourth Military Medical University, Xi'an Shaanxi 710038, China., Lun WH; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China., Zhang YH; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Wang H; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Xia W; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Sun LJ; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Dai LL; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Jiang TY; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Wang MX; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China., Zheng QS; Center for Drug Clinical Research, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China., Peng HY; Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China., Wang Y; Beijing Co-CRO Medical Development Co., Ltd., Beijing 100711, China., Hu M; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China., Liu X; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China., Lu RJ; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China., Hu JH; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China., Sun CC; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China., Xing H; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China., Shao YM; State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China., Xie D; Frontier Biotechnologies Inc., Nanjing, Jiangsu 211122, China. Electronic address: dxie@frontierbiotech.com., Zhang T; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China. Electronic address: zt_doc@ccmu.edu.cn., Zhang FJ; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China. Electronic address: treatment@chinaaids.cn., Wu H; Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China. Electronic address: whdoc@ccmu.edu.cn.
Jazyk: angličtina
Zdroj: The Journal of infection [J Infect] 2022 Sep; Vol. 85 (3), pp. 334-363. Date of Electronic Publication: 2022 Jun 01.
DOI: 10.1016/j.jinf.2022.05.034
Abstrakt: Competing Interests: Declaration of Competing Interest The authors of this manuscript have read the journal's policy and have the following competing interests: CY, MH, XL, RJL, JHH, CCS, and DX have received salary support from Frontier Biotechnologies Inc. All authors had full access to all study data and analyses, and approved the final report. All other authors have declared that no competing interests exist.
Databáze: MEDLINE
Externí odkaz: